CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO


17-August-2011
Cerilliant Introduces New Stable-Labeled Internal Standard for Everolimus-D4

Everolimus-D4, 100 µg/mL E-070
100 ug/mL in Acetonitrile

A stable-labeled internal standard for the immunosuppressant Everolimus, marketed as Zortress® and Certican® for use in organ transplantation and Afinitor® for treatment of kidney and pancreatic cancers. Clinical laboratories quantitate everolimus levels in patient whole blood samples using LC-MS/MS. While many everolimus LC-MS/MS methods use 32-desmethoxyrapamycin or ascomycin as an internal standard, higher levels of variability / lower levels of reproducibility may occur in the analysis along with the potential for interferences. Use of a stable-labeled analog of everolimus is the best choice to minimize variability or mitigate any potential interference in LC-MS/MS analysis.

In addition to other internal standards such as ascomycin  and cyclosporin D, we offer Certified Spiking Solutions® for a wide variety of immunosuppressants used in therapeutic drug monitoring such as sirolimus, tacrolimus, mycophenolic acid, and cyclosporin A.


Cerilliant Certified Solution Standards and Certified Spiking Solutions are manufactured to the highest industry standards. We are accredited to ISO Guide 34 and ISO/IEC 17025 & certified to ISO 13485 and ISO 9001. Our quality system also incorporates cGMP and GLP requirements


All New Product Announcements


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn